BidaskClub upgraded shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a sell rating to a hold rating in a report released on Friday morning.
A number of other brokerages have also recently commented on DBVT. Zacks Investment Research cut DBV TECHNOLOGIE/S from a buy rating to a hold rating in a research note on Thursday, September 13th. Stifel Nicolaus began coverage on DBV TECHNOLOGIE/S in a report on Thursday, September 13th. They issued a buy rating and a $35.00 target price on the stock. Morgan Stanley dropped their target price on DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an equal weight rating on the stock in a report on Tuesday, September 11th. Bank of America dropped their target price on DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a buy rating on the stock in a report on Friday, November 2nd. Finally, ValuEngine upgraded DBV TECHNOLOGIE/S from a sell rating to a hold rating in a report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. DBV TECHNOLOGIE/S has an average rating of Buy and a consensus target price of $33.67.
DBV TECHNOLOGIE/S stock traded down $0.80 during mid-day trading on Friday, reaching $19.20. The stock had a trading volume of 97,222 shares, compared to its average volume of 120,120. DBV TECHNOLOGIE/S has a fifty-two week low of $16.65 and a fifty-two week high of $26.98. The stock has a market capitalization of $1.14 billion, a PE ratio of -5.70 and a beta of 1.23.
Hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of DBV TECHNOLOGIE/S in the second quarter valued at approximately $285,000. Exane Asset Management lifted its holdings in shares of DBV TECHNOLOGIE/S by 17.9% in the second quarter. Exane Asset Management now owns 50,000 shares of the company’s stock valued at $964,000 after purchasing an additional 7,600 shares in the last quarter. First Midwest Bank Trust Division lifted its holdings in shares of DBV TECHNOLOGIE/S by 36.7% in the second quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock valued at $2,642,000 after purchasing an additional 36,798 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of DBV TECHNOLOGIE/S by 842.6% in the first quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock valued at $3,074,000 after purchasing an additional 119,119 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of DBV TECHNOLOGIE/S by 4.7% in the second quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock valued at $5,970,000 after purchasing an additional 14,032 shares in the last quarter. Institutional investors own 44.65% of the company’s stock.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
See Also: What are the Benefits of Index Funds?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.